Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saxenda: Underlying Mechanisms and Clinical Outcomes
NCT02944500Phase 4Active, not recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Nov 2016
- Primary completion
- Jun 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 4 trial of liraglutide in obesity, sponsored by Beth Israel Deaconess Medical Center. Started Nov 2016; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02944500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02944500.